載入...
Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
BACKGROUND: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present the case of a patient treated with alectinib...
Na minha lista:
| 發表在: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
S. Karger AG
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5216233/ https://ncbi.nlm.nih.gov/pubmed/28101031 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000453314 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|